This phase III trial will evaluate the safety and effectiveness of an immunotherapy (nivolumab), given in combination with a chemotherapy (docetaxel), in men with advanced castration-resistant prostate cancer that has gotten worse after second-generation hormone therapy.
This trial is treating patients with castration-resistant prostate cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
You may be excluded from this trial if:
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
Commercial Sponsor
Bristol-Myers Squibb (BMS)
Summary
Eligible patients will be randomised to receive Nivolumab or a placebo-equivalent, in combination with docetaxel and prednisone as a specified dose on a specified day.
Recruiting Hospitals Read More